Table 1.
Demographic and clinical information.
| Parameter | All Group | With TEE Monitoring | Without TEE Monitoring | Mann–Whitney “U” Test/chi2 Test |
|---|---|---|---|---|
| Number of patients | 3185 | 1079 | 2106 | |
| Patient age during TLE (years); x ± SD | 65.720 ± 15.622 N = 3185 |
67.419 ± 14.232 N = 1079 |
64.849 ± 16.223 N = 2106 |
p < 0.001 |
| Patient age at first implantation (years); x ± SD | 57.601 ± 17.036 N = 3185 |
58.096 ± 15.813 N = 1079 |
57.348 ± 17.628 N = 2106 |
p = 0.558 |
| NYHA class; x ± SD | 1.797 ± 0.692 N = 3185 |
2.035 ± 0.564 N = 1079 |
1.676 ± 0.719 N = 2106 |
p < 0.001 |
| NYHA class III & IV; n (%) | 451 (14.160) N = 3185 |
173 (16.033) N = 1079 |
278 (13.200) N = 2106 |
p < 0.05 |
| LVEF [%]; x ± SD | 48.911 ± 15.053 N = 3145 |
48.795 ± 15.852 N = 1070 |
48.971 ± 14.628 N = 2075 |
p = 0.896 |
| LVEF < 40%; n (%) | 879 (27.598) N = 3185 |
331 (30.677) N = 1079 |
548 (26.021) N = 2106 |
p < 0.01 |
| Hemoglobin concentration; (g/dL 0 x ± SD | 12.901 ± 1.946 N = 3121 |
12.589 ± 2.007 N = 1059 |
13.062 ± 1.894 N = 2062 |
p < 0.001 |
| Renal failure, creatinine concentration > 1.3 mg/dL; n (%) | 680 (21.601) N = 3148 |
262 (24.764) N = 1058 |
418 (20.000) N = 2090 |
p < 0.01 |
| Diabetes mellitus; n (%) | 624 (19.592) N = 3185 |
229 (21.223) N = 1079 |
395 (18.756) N = 2106 |
p = 0.107 |
| Arterial hypertension; n (%) | 1852 (58.148) N = 3185 |
572 (53.012) N = 1079 |
1280 (60.779) N = 2106 |
p < 0.001 |
| Coronary artery disease/stroke/peripheral artery disease n; n (%) | 1328 (41.695) N = 3185 |
455 (42.169) N = 1079 |
873 (41.453) N = 2106 |
p = 0.720 |
| Permanent atrial fibrillation; n (%) | 724 (22.732) N = 3185 |
257 (23.818) N = 1079 |
467 (22.175) N = 2106 |
p = 0.316 |
| Prior sternotomy; n (%) | 478 (15.008) N = 3185 |
145 (13.438) N = 1079 |
333 (15.812) N = 2106 |
p = 0.085 |
| Charlson comorbidity index; x ± SD | 4.616 ± 3.621 N = 3178 |
4.972 ± 3.756 N = 1072 |
4.434 ± 3.538 N = 2106 |
p < 0.001 |
Abbreviations: left ventricular ejection fraction (LVEF), N New York Heart Association (NYHSA), transvenous lead extraction (TLE).